Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Check-Cap Ltd Ord (CHEK)

Check-Cap Ltd Ord (CHEK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,288
  • Shares Outstanding, K 1,600
  • Annual Sales, $ 0 K
  • Annual Income, $ -10,590 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.45
  • Number of Estimates 2
  • High Estimate -0.43
  • Low Estimate -0.46
  • Prior Year -0.58
  • Growth Rate Est. (year over year) +22.41%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.60 +28.44%
on 12/23/19
2.37 -13.29%
on 01/09/20
+0.39 (+23.18%)
since 12/20/19
3-Month
1.28 +60.55%
on 11/29/19
2.37 -13.29%
on 01/09/20
+0.32 (+18.10%)
since 10/21/19
52-Week
1.28 +60.55%
on 11/29/19
4.20 -51.07%
on 01/29/19
-0.71 (-25.81%)
since 01/18/19

Most Recent Stories

More News
Check-Cap Announces Positive Results from U.S. Pilot Study of C-Scan® System

Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKW), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of the C-Scan® System, the first and...

CHEK : 2.06 (+1.22%)
CHEKW : 0.01 (unch)
CHEKZ : 0.20 (-20.00%)
Check-Cap Announces $4.75 Million Private Placement

Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKW), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of the C-Scan® System, the first and...

CHEK : 2.06 (+1.22%)
CHEKW : 0.01 (unch)
CHEKZ : 0.20 (-20.00%)
Check Into Cash Owner Allan Jones Sponsors Cleveland Middle School Wrestling, Praises Its First and Undefeated Female Wrestler

Check Into Cash's founder Allan Jones is proudly sponsoring Cleveland High School (Jones' alma mater), which has dominated Tennessee wrestling over the past decade. His company has also sponsored Cleveland...

CHEK : 2.06 (+1.22%)
Check-Cap Reports Third Quarter 2019 Financial Results and Corporate Highlights

Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKW), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of the C-Scan® System, the first and...

CHEK : 2.06 (+1.22%)
CHEKW : 0.01 (unch)
CHEKZ : 0.20 (-20.00%)
Check-Cap to Present at the Dawson James 5th Annual Small Cap Growth Conference

Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKW), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of the C-Scan® System, the first and...

CHEK : 2.06 (+1.22%)
CHEKW : 0.01 (unch)
CHEKZ : 0.20 (-20.00%)
Check-Cap Expands Leadership Team With Appointment of Dr. Vardit Segal as Vice President of Clinical Affairs

Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKW), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of the C-Scan® System, the first and...

CHEK : 2.06 (+1.22%)
CHEKW : 0.01 (unch)
CHEKZ : 0.20 (-20.00%)
CSII : 54.18 (+1.06%)
Check-Cap to Present at the H.C. Wainwright 21st Annual Global Investment Conference

Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKW), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of the C-Scan® System, the first and...

CHEK : 2.06 (+1.22%)
CHEKW : 0.01 (unch)
CHEKZ : 0.20 (-20.00%)
Check-Cap and GE Healthcare Announce Completion of Manufacturing Line Transfer Implementation and Qualification for the C-Scan® System Operated by GE Healthcare

Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKW), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of the C-Scan® System, the first and...

CHEK : 2.06 (+1.22%)
CHEKW : 0.01 (unch)
CHEKZ : 0.20 (-20.00%)
Check-Cap Reports Second Quarter 2019 Financial Results and Corporate Highlights

Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKW), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only preparation-free...

CHEK : 2.06 (+1.22%)
CHEKW : 0.01 (unch)
CHEKZ : 0.20 (-20.00%)
Check-Cap Announces Positive Final Results from Its Post-CE Approval Study of the C-Scan® System

Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKW), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only preparation-free...

CHEK : 2.06 (+1.22%)
CHEKW : 0.01 (unch)
CHEKZ : 0.20 (-20.00%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Trade CHEK with:

Business Summary

Check Cap Ltd. is a medical diagnostics company. The company is engaged in the development of an ingestible imaging capsule for the screening of colorectal cancer. Check Cap Ltd. is based in Mount Carmel, Israel.

See More

Key Turning Points

2nd Resistance Point 2.21
1st Resistance Point 2.13
Last Price 2.06
1st Support Level 2.00
2nd Support Level 1.95

See More

52-Week High 4.20
Fibonacci 61.8% 3.08
Fibonacci 50% 2.74
Fibonacci 38.2% 2.40
Last Price 2.06
52-Week Low 1.28

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar